T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP‐4i in the same period and healthcare setting (Diabetes/Metabolism Research and Reviews)
Diabetes News
Tag: Type 2 Diabetes
Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race
These results support the HbA1c-lowering effectiveness of linagliptin across age, race, and renal function categories among a large real-world population of adults with T2DM (Diabetes Therapy)
Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020
Initiating insulin therapy, is recommended at or near the end of each treatment algorithm (JAMA)
Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility
The purpose of this review is to summarize the literature evidence that faces the pathophysiological mechanisms underlying bone fragility in T2DM patients (Journal of Diabetes Research)
Prevalence of Microvascular and Macrovascular Disease in the Glycemia Reduction Approaches in Diabetes – A Comparative Effectiveness (GRADE) Study Cohort
In the GRADE cohort with <10 years of T2D and a mean HbA1c of 8.0%, diabetes complications were present in a substantial fraction of participants, more so than might otherwise have been expected (Diabetes Research and Clinical Practice)
Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a cohort study in people with diabetes
Deaths in people with diabetes in England have more than doubled during the COVID-19 epidemic. Hyperglycaemia and obesity in both Type 1 and Type 2 diabetes were independently associated with increased COVID-19 mortality. Risk factor control could diminish the impact of COVID-19 in diabetes (NHS England)
Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a whole population study
This nationwide analysis in England demonstrates that all types of diabetes are independently associated with a significant increased risk of in-hospital death with COVID-19 (NHS England)
The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes
In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guidelines recommending standard glycemic control (Diabetes Care)
What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
This study identified patients’ phenotypic characteristics that may have the potential to influence individual treatment response. Accounting for these characteristics in clinical treatment decisions may facilitate individualised prescribing by being able to select the right drug for the right patient (Diabetes Therapy)
Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus
Among older patients with diabetes, mortality risk decreased importantly with three new diabetes drugs, 3 blood pressure drugs and statins. It increased moderately with sulfonylurea and insulin. Studies of aggressive use of new T2DM drugs instead of sulfonylureas and insulin are needed (BMJ Open, Diabetes Research & Care)
Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study
Our results corroborate the hypothesis that HDL cholesterol levels are nonprotective in T2DM patients. The U-shaped association between HDL-cholesterol levels and mortality associated with infectious diseases should be verified by further studies (Journal of Translational Medicine)
Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin‐3 level
Gal3 might be associated with cognitive impairment in type 2 diabetes mellitus, and serum Gal3 level might be a new risk factor of MCI in type 2 diabetes mellitus patients (Journal of Diabetes Investigation)
Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes
Glucose controls glucagon secretion by intrinsic and paracrine mechanisms, but their relative significance is still debated52, and secretory defects in type-2 diabetes are not well understood. The current work is first in using high-resolution microscopy to study glucagon secretion both in intact islets and in single dispersed α-cells of healthy and type-2 diabetic donors, thus isolating intrinsic from paracrine mechanisms while having full control over paracrine signaling (Nature Communications )
Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia
Early combination treatment with linagliptin and metformin can improve the chances of achieving tight glycemic control (HbA1c ≤ 6.5%) without increasing the risk of hypoglycemia or other adverse events (Diabetes Therapy)
Population-based screen-detected type 2 diabetes mellitus is associated with less need for insulin therapy after 10 years
Population-based screen-detected type 2 diabetes is associated with less need for insulin after 10 years compared with people diagnosed during care-as-usual. Glycemic control was better after screen detection but on average good in all groups (BMJ)
Associations of iron markers with type 2 diabetes mellitus and metabolic syndrome
Our results suggest a link between ferritin and T2DM and MetS, which might be partially explained by hepatic dysfunction (Diabetes Research and Clinical Practice)
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study ELLENA‐IT study
Liraglutide addition to ongoing insulin therapy effectively reduced glycated hemoglobin and glycated albumin levels than empagliflozin in patients with inadequately controlled type 2 diabetes (Journal of Diabetes Investigation)
The impact of hyperglycemia on urinary albumin excretion in recent onset diabetes mellitus type II
Hyperglycemic state emerges as a powerful predictor of increased UAE even at the earliest stages of diabetes. The relative contribution of hypertension and macrovascular dysfunction to the development of microalbuminuria seems to be obscured by hyperglycemia, even in patients whose diabetes onset does not exceed a few months’ time(BMC Nephrology)
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
The risk score demonstrated that a high risk of severe hypoglycaemia was associated with a high incidence of MACE and all‐cause mortality and that, in this high‐risk group, those treated with degludec had a lower incidence of MACE. These observations support the hypothesis that hypoglycaemia is a risk factor for cardiovascular events (Diabetes, Obesity and Metabolism)
Metformin Usage Index and assessment of vitamin B12 deficiency among metformin and non-metformin users with type 2 diabetes mellitus
The MUI can be employed as a risk assessment tool for evaluation of vitamin B12 deficiency in patients with T2D. Further prospective studies are required to determine the MUI thresholds in populations with good nutritional statuses and low prevalence of vitamin B12 deficiency (Acta Diabetologica)
- 1
- 2
- 3
- …
- 44
- Next Page »
Glycosmedia is also available as an App: